Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :28910968
Publication Date : 2017/09/15

Efficiency of antibody therapy in demyelinating diseases.


Monoclonal antibody therapy is a new treatment strategy for many types of diseases including cancers and autoimmune diseases, realizing a high efficacy and tolerability. In multiple sclerosis (MS) and neuromyelitis optica (NMO) spectrum disorders, several monoclonal antibodies have been suggested to decrease the incidence of clinical relapse and the disease activity. In MS, anti-α4 integrin (natalizumab), anti-CD52 (alemtuzumab), anti-CD25 (daclizumab) and anti-CD20 (ocrelizumab) have been shown to effectively reduce the relapses in randomized controlled trials and have been approved by the Food and Drug Administration. Specifically, ocrelizumab is the first drug that has shown significant suppression of brain volume loss and suppression of chronic disability progression. In NMO, though there have yet to be any approved monoclonal antibodies, rituximab, anti-complement C5 (eculizumab), anti-IL-6 receptor (tocilizumab), anti-CD19 (inebilizumab) and non-pathogenic anti-aquaporin 4 (aquaporumab) have been suggested to be effective, and some of these are now under clinical trials. Aquaporumab is a non-pathogenic recombinant human monoclonal antibody that competitively inhibits the binding of the pathogenic auto-antibody against aquaporin 4 in NMO patients; thus, it is expected to be highly disease specific with less non-specific adverse events. Some of these monoclonal antibodies in MS and NMO are known to cause several notable adverse events. Natalizumab and rituximab increase the risk of progressive multifocal leukoencephalopathy. Eculizumab increases the risk of meningococcal infection. Tocilizumab is known to cause intestinal diverticulitis that can cause intestinal perforation. In this review, we summarize the characteristics of, evidence for and notable adverse events of each monoclonal antibody in MS and NMO.

Authors : Akaishi Tetsuya , Nakashima Ichiro ,

Related products :

Catalog number Product name Quantity
B437 Brain Heart Infusion w_PABA USE : For examination of blood from patients under sulphonamide therapy. 5x500gm
B437 Brain Heart Infusion w_PABA USE For examination of blood from patients under sulphonamide therapy. Qty per Litre of Medium: 37
orb60678 Verteporfin Verteporfin(Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy. For research use only. 10 mg
27-424 Altered expression of GBX2, part of the homeobox-containing human family of DNA-binding transcription factors, is associated with therapy failure and death in patients with multiple types of cancer. 0.1 mg
27-985 The t (16;21) (q24;q22) translocation is a rare but recurrent chromosomal abnormality associated with therapy-related myeloid malignancies. The translocation produces a chimeric gene made up of the 5' 0.05 mg
28-896 The t (16;21) (q24;q22) translocation is a rare but recurrent chromosomal abnormality associated with therapy-related myeloid malignancies. The translocation produces a chimeric gene made up of the 5' 0.1 mg
ABP-CE-XDHE005 Xtreme Efficiency DH10 5 X 60uL
ABP-CE-XDHE050 Xtreme Efficiency DH10 50 X 60uL
ABP-CE-XDHE025 Xtreme Efficiency DH10 20 X 60uL
FYE608-80VL ECOS™ 101 (DH5α), Efficiency: > 3 x 108 1kit
FYE609-10VL ECOS™ 101 (DH5α), Efficiency: > 1 x 109 1kit
FYE609-80VL ECOS™ 101 (DH5α), Efficiency: > 1 x 109 1kit
FYE507-80VL ECOS™ 10B (DH10B), Efficiency: > 5 x 107 1kit
FYE608-10VL ECOS™ 101 (DH5α), Efficiency: > 3 x 108 1kit
FYE607-80VL ECOS™ 101 (DH5α), Efficiency: > 1 x 108 1kit
FYE607-10VL ECOS™ 101 (DH5α), Efficiency: > 1 x 108 1kit
CS-103 HIGH EFFICIENCY TRANSFER SOLUTION (HETS) 500 ml
FYE709-10VL ECOS™ 9-5 (JM109), Efficiency: > 5 x 108 1kit
FYE610-10VL ECOS™ X (DH5α), Efficiency: > 5 x 109 1kit
FYE610-80VL ECOS™ X (DH5α), Efficiency: > 5 x 109 1kit
FYE507-10VL ECOS™ 10B (DH10B), Efficiency: > 5 x 107 1kit
FYE709-80VL ECOS™ 9-5 (JM109), Efficiency: > 5 x 108 1kit
FYE708-80VL ECOS™ 9-5 (JM109), Efficiency: > 1 x 108 1kit
FYE708-10VL ECOS™ 9-5 (JM109), Efficiency: > 1 x 108 1kit
FYE707-80VL ECOS™ 9-5 (JM109), Efficiency: > 5 x 107 1kit


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur